NCT01342640View on ClinicalTrials.gov

A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 18, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Anemia
Interventions
DRUG

methoxy polyethylene glycol-epoetin beta [Mircera]

Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.

Trial Locations (5)

0

Mansoura Kidney Center; Nephrology, Al Mansurah

Unknown

Alexandria University; Endocrinology Department, Alexandria

El Qahira Al Fatemeya Hospital, Cairo

Kasr El Ainy University Hospital; Endocrinology Department, Cairo

Nasser Institute, Cairo

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01342640 - A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia | Biotech Hunter | Biotech Hunter